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ABSTRACT 
We present a framework  for  detecting possible adverse drug reactions (ADRs) 
using Utah Medicaid administrative data. We examined four  classes of  ADRs 
associated with treatment of  dementia by acetylcholinesterase inhibitors (AChEIs): 
known reactions (gastrointestinal, psychological disturbances), potential reactions 
(respiratory disturbance), novel reactions (hepatic, hematological disturbances), and 
death. 
Our cohort design linked drug utilization data to medical claims from  Utah 
Medicaid recipients. We restricted the analysis to beneficiaries  50 years and older 
who had a dementia-related diagnosis. We compared patients treated with AChEIs to 
patients untreated with antidementia medication therapy. We attempted to remove 
confounding  by establishing propensity-score-matched cohorts for  each outcome 
investigated; we then evaluated effects  of  drug treatment by conditional multivariable 
Cox-proportional-hazard regression. Acute and transient effects  were evaluated by a 
crossover design using conditional logistic regression. 
Propensity-matched analysis of  expected reactions found  that AChEI treatment 
was associated with gastrointestinal episodes (hazards ratio [HR]: 2.02; 95% 
confidence  interval [CI]: 1.28-3.2) but not psychological episodes, respiratory 
disturbance, or death. Among the tested unexpected reactions, the risk was higher 
with hematological episodes (HR: 2.32; 95% CI: 1.47-3.6) but not hepatic episodes. 
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We also noted a trend towards an increase in the odds of  experiencing acute 
hematological events in the treated group (odds ratio [OR]: 3.0; 95% CI: 0.97-9.3). 
We observed an expected association between AChEIs and gastrointestinal 
disturbances and detected a signal of  hematological adverse drug events (ADEs) after 
treatment with AChEIs in this pilot study. Using our analytic framework  may raise 
awareness of  potential ADEs and generate hypotheses for  future  investigations. 
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I  have not failed,  I've  just found  10,000 ways that won't  work. 
(Thomas Alva Edison, 1847-1931) 
Pharmaceuticals, like all healthcare interventions, offer  benefits  to patients but 
also pose risks of  harm in the form  of  negative side effects  and adverse events. The 
U.S. Food and Drug Administration (FDA), in regulating drugs for  the U.S. 
marketplace, relies in part on safety  data generated by randomized controlled trials, 
but the limitations of  such data are widely recognized because of  the characteristics of 
such trials (e.g., highly selected settings and patient populations, short duration of 
studies, and less reporting of  such information  than of  positive outcomes). Other 
sources of  information,  including various types of  observational studies, voluntary 
schemes for  reporting adverse events, and more organized postmarketing surveillance 
studies, contribute to the knowledge base about drug safety  and tolerability. 
Recent reports underscore the need for  such methods, particularly to detect 
serious but rare adverse events that were not discovered during premarketing trials. 
For example, cyclooxygenase 2 inhibitor nonsteroidal anti-inflammatory  drugs 
(commonly known as COX-2 inhibitors, used for  pain management) are documented 
to increase cardiac morbidity (1,2); antipsychotic medications (especially atypical 
antipsychotics) are associated with an increased risk of  mortality in the elderly (3). 
These types of  findings  also prompt questions about morbidity and mortality in elderly 
or frail  individuals who are exposed to other classes of  drugs. 
The enactment of  the Medicare Prescription Drug, Improvement and 
Modernization Act of  2003, which introduced the Part D benefit  for  outpatient 
medications for  Medicare beneficiaries,  affords  an opportunity to examine adverse 
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but the limitations of such data are widely recognized because of the characteristics of 
such trials (e .g., highly selected settings and patient populations, short duration of 
studies, and less reporting of such information than of positive outcomes). Other 
sources of information, including various types of observational studies, voluntary 
schemes for reporting adverse events, and more organized postmarketing surveillance 
studies, contribute to the knowledge base about drug safety and tolerability . 
Recent reports underscore the need for such methods, particularly to detect 
serious but rare adverse events that were not discovered during premarketing trials . 
For example, cyclooxygenase 2 irthibitor nonsteroidal anti-inflammatory drugs 
(commonly known as COX-2 irthibitors, used for pain management) are documented 
to increase cardiac morbidity (1,2); antipsychotic medications (especially atypical 
antipsychotics) are associated with an increased risk of mortality in the elderly (3). 
These types of findings also prompt questions about morbidity and mortality in elderly 
or frail individuals who are exposed to other classes of drugs. 
The enactment of the Medicare Prescription Drug, Improvement and 
Modernization Act of 2003, which introduced the Part D benefit for outpatient 
medications for Medicare beneficiaries, affords an opportunity to examine adverse 
events in large administrative claims databases through linking prescription drug 
claims with medical claims. Because Medicare beneficiaries  often  have a complex 
array of  health issues managed by multiple medications, this population is at risk for 
complications resulting from  drug safety  issues. The presumed availability of 
information  from  the Center for  Medicare and Medicaid Services, including databases 
that would combine Part A, Part B, and Part D information,  is expected to provide a 
unique opportunity to study how prescription drugs are used in this population, the 
positive and negative effects  of  prescription use, and the outcomes of  such use. 
The Agency for  Healthcare Research and Quality requested the Research 
Triangle Institute's Developing Evidence to Inform  Decisions About Effectiveness 
Center to take on a specific  project to develop methods for  identifying  adverse drug 
events (ADEs) and adverse drug reactions (ADRs) in databases that could mimic 
those eventually presumed to be available to Medicare beneficiaries.  In principle, 
Medicare pharmacy and claims databases will be ideal for  large postmarketing 
surveillance studies of  ADRs. In practical terms, databases that include outpatient 
pharmacy data are not yet available from  the Center for  Medicare and Medicaid 
Services because the Part D benefit  is so new. For that reason, the Agency for 
Healthcare Research and Quality assigned us the task of  exploring how best to use 
similar databases and to develop and test methods and measures for  studying 
medication safety  in the elderly. 
To apply methods and test measures appropriately, research must examine the 
application of  measures before  implementing them nationally. In proceeding this way, 
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the Agency for  Healthcare Research and Quality aims to offer  new resources and 
tools for  numerous stakeholders, including those in pharmacoepidemiology and 
pharmacoeconomics, for  studying and understanding the use, benefits,  and risks of 
pharmaceuticals, and for  doing so in advance of  the appearance of  Parts A, B, and D 
Medicare data. Our work contributes to this methodological toolbox and develops a 
data analytical framework  for  pharmacoepidemiological research on ADRs using 
population-based claims and administrative data sources. 
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We present a framework  for  detecting possible adverse drug reactions (ADRs) 
using Utah Medicaid administrative data. We examined four  classes of  ADRs 
associated with treatment of  dementia by acetylcholinesterase inhibitors (AChEIs): 
known reactions (gastrointestinal, psychological disturbances), potential reactions 
(respiratory disturbance), novel reactions (hepatic, hematological disturbances), and 
death. 
Methods 
Our cohort design linked drug utilization data to medical claims from  Utah 
Medicaid recipients. We restricted the analysis to beneficiaries  50 years and older 
who had a dementia-related diagnosis. We compared patients treated with AChEIs to 
patients untreated with antidementia medication therapy. We attempted to remove 
confounding  by establishing propensity-score-matched cohorts for  each outcome 
investigated; we then evaluated effects  of  drug treatment by conditional multivariable 
Cox-proportional-hazard regression. Acute and transient effects  were evaluated by a 
crossover design using conditional logistic regression. 
Propensity-matched analysis of  expected reactions found  that AChEI treatment 
was associated with gastrointestinal episodes (hazards ratio [HR]: 2.02; 95% 
confidence  interval (CI): 1.28-3.2) but not psychological episodes, respiratory 
disturbance, or death. Among the tested unexpected reactions, the risk was higher 
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We also noted a trend towards an increase in the odds of  experiencing acute 
hematological events in the treated group (odds ratio: 3.0; 95% CI: 0.97-9.3). 
Conclusions 
We observed an expected association between AChEIs and gastrointestinal 
disturbances and detected a signal of  hematological adverse drug events (ADEs) after 
treatment with AChEIs in this pilot study. Using our analytic framework  may raise 
awareness of  potential ADEs and generate hypotheses for  future  investigations. 
Introduction 
Despite its limitations, the U.S. Food and Drug Administration's (FDA) 
Adverse Event Reporting System (AERS) has successfully  identified  rare and 
unexpected adverse events (1-3). In many studies, administrative data sources have 
been used to estimate the extent of  the problem or to confirm  safety  signals identified 
from  AERS (4,5). However, fewer  studies have demonstrated the potential of 
administrative data for  first-line  adverse drug reaction (ADR) surveillance (6). In this 
pilot study, we present a framework  for  directed discovery of  possible ADRs using 
population-based administrative data sources, an approach intended to complement the 
FDA's adverse reporting system. 
We examined associations between drug use and possible ADRs resulting from 
treatment of  dementia with acetylcholinesterase inhibitors (AChEIs), namely, 
donepezil hydrochloride, rivastigmine tartrate, and galantamine hydrobromide. We 
measured associations for  four  classes of  ADEs—established reactions (gastrointestinal 
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and psychological disturbances), potential reactions based on drug pharmacology 
(respiratory disturbance), novel unexpected reactions (hepatic and hematological 
disturbances), and death. Hepatic and hematologic syndromes were evaluated because 
they are two examples of  potentially fatal  reactions that have been found  in 
postmarketing surveillance of  drug-induced disease (7). 
Methods 
The directed discovery framework  consists of  clinical framing,  data 
preparation, event detection, and hypothesis generating and testing. The first  three 
components are described in the Methods; hypothesis generating and testing are 
explored in the Discussion. 
Clinical Framing and Data Preparation 
Clinical framing  consisted of  reviewing the medical literature and consulting 
clinical experts to define  the treatment groups, inclusion criteria, drug courses, 
outcomes, and covariates. 
Sources. Data consisted of  pharmacy and medical claims and enrollment status 
from  Utah Medicaid recipients in the fee-for-service  program between 1/01/2003 and 
12/31/2005. We linked Utah death certificate  data to Medicaid recipients by a 
deterministic method using social security number. To protect patients' privacy, all 
potentially traceable personal identifiers  were removed. The University of  Utah 
Institutional Review Board approved this study. 
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Subjects. We studied Utah Medicaid recipients' ages 50 and older with a 
dementia-type diagnosis (Appendix A). As Medicaid enrollment occurs on a monthly 
basis, we tracked membership enrollment and deenrollment and censored patients 
when enrollment was terminated and not reestablished within the study period. 
Because of  the relatively high rate of  sustained enrollment, approximately 99% of  the 
cohort were enrolled for  at least 80% of  the months from  their first  until their last 
month of  eligibility or until the study period ended. We did not limit inclusion to 
continuously enrolled recipients. 
Treatment groups. We inferred  patient AChEI use by reconstructing courses of 
AChEI therapy from  pharmacy claims data. To achieve greater homogeneity among 
users' disease stage and risk for  adverse reactions (8), we restricted the AChEI cohort 
to the first  incident course of  AChEI therapy, which was defined  as their first  course 
with at least a 180-day drug-free  period. To ensure that patients were receiving 
medical care during the 180-day drug-free  period and not receiving the drug 
elsewhere, recipients had to be enrolled and to have at least one medical claim during 
the 180-day drug-free  (baseline) period. We defined  a course of  AChEI therapy as 
beginning on the week the drug was first  dispensed and ending on day 60 after  a 
continuous gap in their drug supply of  > 60 days (Figure 2.1). 
The untreated comparison group consisted of  Medicaid recipients 50 years and 
older with a dementia-like diagnosis who did not receive AChEI therapy. We 
established a 180-day baseline period during which recipients were enrolled and had 
at least one medical claim. The index date for  individuals in the untreated group 
10 
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Figure  2.1. Treatment time windows for  cohort and cohort crossover study. 
AChEI = acetylcholinesterase inhibitors 
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11 
began at the first  dementia-related outpatient visit that allowed for  a 180-day baseline 
period. Starting time zero with a dementia-related outpatient visit established an 
indicated population that was engaging the healthcare system. 
Outcomes. As noted earlier, our primary clinical outcomes were 
gastrointestinal, psychological, respiratory, hematological, and hepatic conditions, and 
death. We identified  healthcare visits related to each clinical outcome in professional 
and facility  claims using Healthcare Cost and Utilization Project (HCUP) Clinical 
Classification  Software  (CCS) codes, which are documented in Appendix A. As 
primary diagnosis typically indicates the reason for  seeking medical care or the most 
important problem at the visit, we limited outcome detection to primary diagnosis 
codes. We tailored outcome classifications  for  each study design, which are described 
under Event Detection. Our analysis also measured the association of  AChEI use with 
death. 
Potential confounding.  We assessed demographic variables, comorbidities, 
drug therapy, and indicators of  healthcare utilization as potential confounders. 
Comorbidity indices included HCUP comorbidity software  version 3.2 and the 
modified  RxRisk-V (RxRisk-Vm) score, which infers  comorbidity using pharmacy 
claims (9). We measured healthcare utilization by the number of  outpatient visits, 
hospitalizations, and emergency department visits, and we also accounted for  the use 
of  hospice services and nursing home care. 
We considered specific  classes of  medications as potential confounders, 
specifically,  antianxiolytics, anticonvulsants, Parkinson's treatment, antidepressants, 
12 
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antipsychotics, steroids, narcotics, respiratory agents, anticoagulants, corticosteroids, 
and sedatives. We treated use of  statin drugs as an indicator of  health status because 
they are preferentially  prescribed to healthier, less frail  patients who are not at the 
end of  life  (10). 
Person time units. We constructed the final  analytic table using 1-week 
discrete time intervals; that is, changes in covariate status, medication use, and 
outcomes are captured weekly. This interval maximizes efficiency  without omitting 
clinically important changes in patient outcome and covariate status. All database 
manipulation was conducted in SAS 9.2. 
Event Detection 
Cohort Design 
We used an open cohort design with a matching propensity score to explore 
associations between data on drug utilization and possible ADRs. We used propensity 
scores to address covariate imbalance using logistic regression models to predict 
AChEI treatment. We included confounders  and risk factors  in the propensity score 
models (11). Because we included risk factors  along with confounders,  we built 
separate propensity score models and matched cohorts for  each study outcome. Two 
physicians who routinely treat patients with dementia independently selected variables 
to construct propensity score models. They discussed disagreements to arrive at 
consensus. Variables for  each model are listed in Appendix B. 
Our analyses included propensity score matching followed  by additional 
matching on key prognostic covariates (12). For example, we performed  propensity 
13 
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matching with covariate matching for  whether an individual had a gastrointestinal visit 
during the baseline period when evaluating the gastrointestinal outcome. Analysis of 
death consisted of  propensity score matching and covariate matching for  baseline age 
and hospice care. 
Clinical endpoints were intended to measure increased healthcare utilization 
associated with specific  diagnoses. We defined  episodes of  care to differentiate 
clusters of  events and to reduce the impact of  immediate clinical exuberance 
associated with a new episode of  care. A 4-week gap in claims for  each clinical 
outcome was required to initiate a new episode. For each study endpoint, we 
calculated incidence densities per 100 patient years. 
We established matched untreated cohorts using Mahalanobis metric matching 
(13). Baseline characteristics of  patients in the AChEI treated and matched untreated 
cohorts were compared using Student's t tests and chi-square tests. We used 
conditional, multivariable, Cox-proportional hazard models that allowed for  recurrent 
events to assess the effect  of  AChEI on specific  clinical endpoints (14). All statistical 
analyses were performed  with Stata MP 9.2 for  Windows. 
Cohort-Crossover Design 
We established three 6-week time windows (i.e., pretreatment, first  treatment, 
and second treatment) to assess acute and transient effects  of  AChEI treatment 
(Figure 2.1). The index week for  the pretreatment window was the week following 
the most recent clinic visit for  any condition during the baseline period. 
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To capture acute effects  of  AChEI treatment, we used the week the AChEI 
was first  dispensed as the index week for  the first  treatment window. We compared 
the odds of  experiencing an event during that window with the odds of  experiencing 
an event during the pretreatment window to identify  acute treatment effects.  To 
evaluate the transience or stability  of  possible ADRs, we compared the odds of 
experiencing an event during the second treatment window with the odds of 
experiencing an event during the pretreatment window. Patients were noted as having 
an event if  they had a medical claim with the primary clinical diagnosis code of 
interest; we used only one event per time window. Odds ratios between the referent 
and treatment windows were computed using conditional logistic regression. 
Results 
Description of  Study Population 
Of  the 29,046 eligible patients in the study populations, 4,109 had a medical 
claim with a dementia diagnosis between 1/01/2003 and 12/31/2005. The AChEI-
treated cohort consisted of  976 total users and 332 users with incident courses; of  the 
latter, 224 were started on donepizil, 59 on rivastigmine, and 49 on galantamine. 
Because numbers of  incident users of  specific  AChEIs were small, we did not assess 
potential ADRs for  individual drugs. In the AChEI treated group, the median duration 
of  incident courses was 33.4 weeks with an interquartile range from  15 to 68.5 
weeks. The median proportion of  weeks for  which the AChEI treated group was 
estimated to have access to the medication at least 1 day during the week was 100%, 
with an interquartile range of  95%-100%. The untreated cohort consisted of  2,968 
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patients who were diagnosed with dementia but did not receive medication to treat the 
disorder during the study period (Figure 2.2). 
Basic characteristics of  the study population during the 6-month baseline 
period are presented in Table 2.1. Compared with the untreated population, incident 
AChEI users were slightly younger, had fewer  HCUP comorbidities, fewer  clinic 
visits, and a lower frequency  of  hospice care. Incident AChEI users also had a higher 
frequency  of  statin use and nursing home care. RxRisk-Vm scores and the average 
numbers of  hospitalizations and emergency department visits were similar for  AChEI 
users and nonusers (untreated patients). 
After  propensity score matching for  each clinical endpoint, the two groups 
were similar on all variables for  each outcome-based cohort, except for  the average 
number of  emergency department visits, which were slightly higher in the untreated 
matched groups for  the evaluation of  respiratory and hepatic episodes (Appendix B). 
In general, the lack of  statistically significant  differences  between the AChEI treated 
and untreated groups on propensity-adjusted variables suggests balance in measured 
covariates between treatment groups. 
Table 2.2 presents incidence densities per 100-person years and 95% 
confidence  intervals for  the complete untreated population and propensity-matched 
comparisons. Table 2.3 presents hazards ratios for  all unadjusted and matched 
comparisons. 
Crude analyses. In bivariate analysis (Table 2.3), we did not observe a higher 
rate of  gastrointestinal episodes in the group treated with AChEIs than in the 
16 
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Table  2.1. Basic Characteristics of  the Study Population, 2003-2005 
Patient Characteristics 
AChEI Cohort 
(n  = 332) 
Untreated Cohort 
(n  = 2,968) P Value 
Average age, years (SD) 76.4(11.4) 77.9(12.4) 0.02 
Frequency female  (Yes = 1) 71% 72.6% 0.53% 
Average number of  HCUP 
comorbidities (SD) 
1.1(1.5) 1.3(1.6) < 0.00 
Average RxRisk-Vm (SD) 4.4(3.1) 4.5(3.3) 0.58 
Average number of  hospitalizations 
(SD) 
0.19(0.45) 0.17(0.5) 0.44 
Average number of  ED visits (SD) 0.11(0.51) 0.11(0.58) 0.17 
Average number of  clinic visits (SD) 15.9(14.3) 16.7(16) < 0.00 
Receiving hospice care (Yes = 1) 0.6% 3.2% < 0.00 
Frequency of  statin dispensed 
(Yes = 1) 
25.6% 16.4% < 0.00 
Frequency of  nursing home stay 
(Yes = 1) 
25.9% 14.4% < 0.00 
AChEI = acetylcholinesterase inhibitors 
HCUP= Healthcare Cost and Utilization Project 
SD  = standard deviation 
% = percent 
ED = emergency department 
RxRisk-Vm = modified  RxRisk-V 
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Table  2.2. Crude Incidence Densities (Per 100-Person Years) of  Target Events in AChEI Treated and Untreated Groups 
AChEI Treated Cohort Untreated Cohort Matched Untreated Cohort 























24.5, 30.7 878 
45.8, 54.2 1399 
28.9, 35.6 1004 
21.8, 27.8 651 








24.8, 26.5 63 
39.8, 42.0 159 
28.4, 30.3 84 

















CI = confidence  interval 
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Table  2.3. Unadjusted and Matched Analysis Comparing Target Outcomes for  Groups Treated and Untreated With 
AChEI Therapy 
Crude Propensity Matched 














































HR = hazards ratio 
CI = confidence  interval 
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untreated group. The rates of  psychological episodes, respiratory episodes, 
hematological episodes, and hepatic episodes were slightly higher, but not statistically 
significant,  in the group treated with AChEIs than in the untreated group. The rate of 
death was significantly  lower in the group treated with AChEIs than in the untreated 
group. 
Propensity-matched analyses. We observed significantly  higher rates of 
gastrointestinal episodes (HR: 2.02; 95% CI: 1.28-3.2) and hematologic episodes 
(HR: 2.32; 95% CI: 1.47-3.67). in the AChEI-treated group than in the propensity-
matched untreated group (Table 2.3). For psychological episodes, respiratory 
episodes, and hepatic episodes, we observed higher, but not statistically significant, 
rates in the AChEI-treated group than in the propensity-matched untreated group. We 
observed a weak and nonsignificant  association between AChEI treatment and 
mortality. 
Cohort-crossover analysis. In cohort-crossover analysis, we did not observe an 
increased odds of  experiencing gastrointestinal events during either the first  or second 
treatment windows. We observed an acute, but nonsignificant,  effect  of  AChEI 
treatment on the odds of  experiencing a psychological event during the first-treatment 
window; it was not sustained during the second-treatment window. We observed 
acute, but nonsignificant,  effects  of  AChEI treatment on the odds of  experiencing a 
respiratory event and hematological events during the first-treatment  window; both 
rates appeared to decrease during the second-treatment window. The acute effect  of 
AChEI treatment on the odds of  experiencing a hepatic event during the first-
21 
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treatment window was imprecise and appeared to decrease during the second-
treatment window (Table 2.4). 
Discussion 
We developed a cohort-based framework  for  using population-based 
administrative data to identify  known ADRs and to discover ADRs that may have 
gone unnoticed during clinical trials. We evaluated AChEI therapy in persons with 
dementia, considering a composite of  possible ADRs (i.e., expected, suspected, 
unexpected reactions, and death) to demonstrate that our analytic techniques produced 
expected results. We used propensity score matching and a within-subject design in an 
attempt to handle confounding.  Our pilot study examined data from  patients diagnosed 
with dementia for  both cumulative effects  of  AChEI treatment and acute effects 
following  initiation of  AChEI therapy. We demonstrated our approach with Medicaid 
data from  the state of  Utah; nonetheless, the framework  presented here can be 
transferred  for  use with other health insurer databases, including the Medicare Parts 
A, B, and D data now available. 
A pervasive issue in pharmacoepidemiologic studies is confounding  by 
indication (15). This problem arises because factors  that influence  treatment choices 
made by clinicians also influence  outcomes. Confounding  by indication can bias the 
crude association between drug treatment and outcomes in either direction and with 
unknown magnitude. Propensity score models are one method used in 
pharmacoepidemiologic studies to balance measured confounders  with the goal of 
making the treatment groups exchangeable. 
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Table  2.4. Cohort Crossover Design: Evaluation of  Acute and Transient Effects  of  AChEI Treatment 
Pretreatment First Treatment Window Second Treatment Window 
Type of  Reactions Measures (n  = 271) (« = 312) (n  = 303) 
Expected reactions 
Gastrointestinal events Events 11 10 11 
OR (95% CI) t 0.7 (0.27, 1.84) 0.86 (0.29, 2.6) 
P value 0.47 0.78 
Psychological events Events 28 39 30 
OR (95% CI) t 1.5 (0.72, 3.3) 0.86 (0.40, 1.9) 
P value 0.26 0.7 
Suspected reactions 
Respiratory events Events 12 14 15 
OR (95% CI) t 1.4 (0.44, 4.4) 1.2 (0.37, 3.9) 
P value 0.57 0.76 
Unexpected reactions 
Hematological events Events 5 13 9 
OR (95% CI) t 3 (0.97, 9.3) 1.75 (0.51, 6.0) 
P value 0.06 0.37 
Hepatic events Events 2 6 1 
OR (95% CI) t 5 (0.58, 42.8) 0.5 (0.05, 5.5) 
P value 0.14 0.57 
OR = odds ratio 
CI = confidence  interval 
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In this study, we addressed confounding  by indication by developing 
propensity score models for  each study outcome. Theoretical confounders  available in 
the data were included in each model to reduce bias. Before  matching, the untreated 
group appeared to be more frail  than the treated group; they had a higher proportion 
of  hospice care, more comorbidity, and a lower proportion of  statin users, which 
suggested less aggressive care because of  poorer health. As one would expect, the 
unadjusted analysis made AChEI treatment appear protective against mortality when 
compared with the untreated group (HR: 0.66; 95% CI: 0.52-0.82), which is not 
supported by clinical trials or other observation studies (16,17). After  propensity and 
covariate matching, we found  no difference  between the AChEI treated and untreated 
groups (HR: 1.07; 95% CI: 0.74-1.54). This illustrates the importance of  addressing 
confounding  by indication when designing ADE surveillance systems. 
An alternative approach to addressing confounding  is to use inverse probability 
weighting methods to model time-varying treatments and confounders.  In simulation 
studies, these methods were less biased than conventional methods when time-varying 
confounding  was present (18). When allowing treatment to be time-varying, we 
observed gastrointestinal disturbance and discovered hematological disturbance; we 
noted the same findings  as if  follow-up  began at initiation of  drug treatment (data not 
shown). Future work should explore the presence of  time-varying confounding  and the 
benefits  of  using inverse probability weighting methods to discover novel ADEs 
associated with drug treatments. 
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To evaluate possible acute and transient effects  of  AChEI treatment, we 
employed cohort-crossover analyses. Typically, in cohort-crossover analyses, events 
are compared between treated and untreated time windows for  each individual. A 
major benefit  of  this within-subject design is that each person acts as his or her own 
control (19,20). It also accounts for  confounding  by indication and other time-
invariant and difficult-to-measure  confounders.  The drawback of  such designs 
involves changes in treatment utilization that are influenced  by health status or the 
study endpoints in question (21). For example, when day-level drug utilization data 
are inferred  from  dispensing history, determining whether adverse effects  are truly 
transient or the result of  a decrease or discontinuation of  drug treatment is difficult. 
Ultimately, we deemed cohort-crossover analysis the best option to discover acute and 
transient effects  because of  its simplicity and ability to remove time-invariant 
confounding  by indication. 
Hypothesis Generating and Testing 
The method described here is a promising approach for  discovering possible 
ADRs such as the association we found  between AChEI use and hematological 
disturbance. In support of  the analytical effectiveness  of  these procedures, our 
approach observed an association with an expected reaction, gastrointestinal 
disturbances. The findings  from  the two study designs, however, were not consistent. 
Our inability to find  an acute increase of  gastrointestinal events in the first-treatment 
time window may be attributable to insensitivity of  claims-based coding to identify 
symptoms of  gastrointestinal disturbance. 
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Despite the fact  that our approach detected a significant  association with one 
expected reaction, gastrointestinal disturbance, it failed  to identify  a strong positive 
association with the second expected reaction, psychological disturbance. We found  a 
higher rate of  psychological episodes in the propensity-matched analysis; nevertheless, 
the association was not statistically significant.  We did, however, observe higher odds 
of  experiencing psychological events in the first-treatment  time window than in the 
pretreatment time window. Even though the higher odds ratio was expected, it did not 
reach significance.  This result can likely be attributed to a combination of  factors. 
First is the low power in the crossover design, and second may be insensitivity of 
claims-based coding to identify  symptoms of  psychological disturbance. 
We discovered no clear associations between AChEIs and respiratory 
disturbance or death. In a recent sequence symmetry analysis, initiators of  AChEI had 
no detectable increased rate of  complications of  chronic airway disorders (22). We 
found  no clear evidence of  an increase or decrease in mortality associated with AChEI 
treatment in published studies or meta-analysis with which to compare our results 
(16). 
Our analysis of  unexpected reactions discovered a statistically significant 
positive association between AChEI treatment and hematological episodes. 
Hematological events also appeared to be positively associated with early AChEI 
treatment. A detailed review of  results with hematological event subcategories (not 
reported here) found  that the rate of  anemia was much higher in the AChEI treated 
group than in the untreated group during the first  6 weeks of  drug treatment. Further 
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analysis is required to determine if  this higher rate is causally associated with 
initiating antidementia drug treatment. At present, no known pharmacologic or 
obvious empirical reasons can explain the reasons that recently marketed AChEI drugs 
cause hematological toxicity. 
The incidence of  hepatic disturbance appeared to be higher in the treated 
group, although nonsignificant,  in both the crossover and propensity matched design. 
Hepatotoxicity was a major safety  concern with tacrine, which is one reason it is not 
commonly used; hepatotoxicity has not been reported for  other AChEIs (23). Larger 
observational studies are needed to determine whether an association exists between 
AChEIs and hepatotoxicity. 
Limitations 
The results from  this study are considered hypothesis generating rather than 
identifying  causal treatment effects.  Causal studies require validation of  treatments, 
outcomes, and covariate classifications.  Furthermore, causal studies require a stronger 
theoretical understanding and explication of  the underlying causal relationships 
between the treatment and outcomes. 
We compared AChEI treated patients, with an incident AChEI course of 
therapy, with an untreated cohort of  patients with a dementia diagnosis. Other options 
were to compare directly the safety  of  AChEI products with one another or to 
compare the safety  of  AChEI therapy with the safety  of  other classes of  medications 
used to treat such patients' dementia. We did not have power to compare individual 
drug products. Treatment with AChEIs is not directly comparable to treatment with 
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memantine, a glutamaterginc N-methyl D-aspartate (NMDA) receptor antagonist 
because memantine is typically not first-line  treatment for  dementia; rather, it is used 
in addition to an AChEI therapy, complicating any comparison. 
In pharmacoepidemiologic studies, an untreated referent  group can also be 
defined  as patients with an incident course of  a medication that is not associated with 
the indication or evaluated outcomes. This type of  "active control group" is likely to 
be more similar to the treated group with regard to activation of  the healthcare system 
than the indicated but untreated group (17). Drug dispensing signifies  that the patient 
has activated the health system. In addition, prescription of  a new medication is likely 
to result in closer monitoring and evaluation of  an individual's health status. The 
primary concern when comparing treated with untreated groups is underrecording of 
health conditions, making the members of  the comparison group seem healthier than 
they really are, which can lead to overestimation of  the effect  of  drug treatment. 
Because of  the multiple outcomes in this study, we were unable to identify  a 
single medication that could yield comparable cohorts for  all events. Instead, we used 
a dementia-related visit, not drug dispensing, as the index date for  the untreated 
group. For both cohorts, the median amount of  time to a clinic visit following  the 
index date was 3 weeks, and the longitudinal visit process was also similar. These 
patterns suggest that healthcare access and followup  may have been similar for  the 
two groups. 
Another limitation of  this study is the small number of  subjects in the AChEI 
treatment group. This markedly limited our ability to confirm  expected adverse effects 
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of  AChEI treatment and discover adverse events that may have gone undetected in 
clinical trials. 
Future Research 
Discovery of  an association between a drug treatment and a theoretical 
reaction, an idiosyncratic reaction, or death is considered hypothesis generating. 
Confirmation  requires additional observational and possibly experimental studies. 
Ideally, discovered associations would first  be confirmed  in large, disparate data 
sources to reproduce evidence of  the association across different  populations. In May 
2008, the FDA published The Sentinel Initiative report to present the national strategy 
for  monitoring medical product safety  (24). Their approach primarily establishes a 
nationwide health information  network for  confirmation  of  safety  signals across 
multiple large databases. Additional observational studies using richer clinical 
information  such as electronic health records or prospectively designed studies, 
however, may be needed to characterize the causal relationship between a drug 
treatment and adverse outcome. 
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Previous adverse drug reaction (ADR) studies have often  relied on data from 
federal  reporting agencies such as MedWatch at the U.S. Food and Drug 
Administration and on information  from  randomized controlled trials. Our study 
presents a methodological framework  for  researchers to use in working with 
observational data, specifically  from  pharmacy and medical claims databases. The 
methods outlined in this report and the stepwise approach (i.e., clinical framing,  data 
preparation, event detection, and hypothesis generation) can be adapted for  other 
comparative safety  and effectiveness  research questions and for  other types of  clinical 
and administrative data. 
Data available from  Medicaid claims, employer claims, and (eventually) 
Medicare claims can be used to examine specific  drug classes and agents within those 
drug classes for  ADRs. The framework  of  initially examining known events from  the 
clinical trials and then potentially severe but unobserved events (as, in our study, 
hepatological and hematological events) will further  our understanding of  drug safety. 
The advantage of  the framework  and method outlined in this work is that they allow 
claims databases to be used for  identification  of  novel signals for  previously 
unrecognized ADRs as well as to examine the number of  previously identified  ADRs. 
Lessons Learned 
The use of  Medicaid data to support detection of  ADRs presents a number of 
significant  challenges. One requirement is to perform  data quality checks meticulously 
in order to identify  obvious errors that might compromise study validity. We followed 
a standard template to evaluate data integrity (1). This useful  and timesaving step 
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identified  a discrepancy, which was subsequently corrected, in the way data were 
extracted across different  years. 
One important condition in developing a research database is to fully 
understand the original data source. Utah Medicaid data and death certificate  data are 
stored in a complicated warehouse. Relationships among different  data tables, 
definitions,  and labels of  data field  are not always clearly documented (or documented 
at all). For example, we had four  different  client identifications.  With careful 
consultation from  Medicaid data experts, we used each of  the identifiers  to link client 
records according to the source of  records and purpose of  linkage. 
The Utah Medicaid program updates its data warehouse structure periodically, 
posing special challenges for  standardizing longitudinal data over the years. We 
learned that the method of  downloading the 2003 pharmacy claims differed  from  the 
method used for  later years. The Utah Department of  Health spent considerable 
resources to prepare and reprepare the raw data files  and intermediate tables for 
researchers to produce analysis tables for  this study. Other state Medicaid data 
warehouses and Medicare data may face  similar challenges. We recommend that 
researchers who are new users of  a state's Medicaid data obtain adequate technical 
support from  the relevant Medicaid program(s) and share their data integrity analysis 
with their data suppliers. 
Future Work 
The framework  presented here is just the tip of  the iceberg in the development 
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medical claims and clinical data. Additional work is needed to standardize data quality 
evaluation, assess drug exposure, validate covariate and outcome assessment, design 
and statistically evaluate unique with comparative effectiveness  research, and report 
these steps. 
This research has led to further  refinement  of  the SAS modules used to 
classify  drug exposure (i.e., course generator) and modules used to organize data by 
discrete time units. The goal is to develop a library of  publically available, production 
quality SAS modules with specific  functions  (e.g., polypharmacy detector; course 
generator; time-structure generator; and programs to organize data for  nested case-
control, cross-over, and longitudinal designs) to share with other 
pharmacoepidemologists in order to improve transparency and reproducibility of 
comparative safety  and effectiveness  research. These modules will also support rapid 
evaluation to newly suspected or possible ADRs. 
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DEMENTIA CODES AND TARGETED OUTCOMES CODES 






Table  A.l. Dementia Codes and Targeted Outcomes Codes From the Healthcare 
Cost and Utilization Project 




























Senile dementia; uncomplicated 
Arteriosclerotic dementia 
Presenile dementia; uncomplicated 
Senile dementia with delirium 
Other senility and organic mental disorders 
Gastritis and duodenitis 
Other disorders of  stomach and duodenum 
Noninfectious  gastroenteritis 
Other and unspecified  gastrointestinal disorders 
Nausea and vomiting 
Abdominal pain 
Anemia 
Coagulation and hemorrhagic disorders 
Diseases of  white blood cells 
Other hematological conditions 
Liver disease 
Affective  disorders 
Other psychoses 
Anxiety, somatoform,  dissociative, and personality 
disorders 
Other mental conditions 
Chronic obstructive pulmonary disease and 
bronchiectasis 
HCUP = Healthcare Cost and Utilization Project 
CCS = Clinical Classification  Software 
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APPENDIX B 
BASELINE COMPARISONS FOR ALL VARIABLES INCLUDED 




Table  B.l. Baseline Comparisons for  All Variables Included in Each Matched Cohort Analysis 
AChEI Gastrointestinal Psychological Respiratory Hepatic Hematologic Death 
Baseline Tx UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value 
Age (years) 76.4 78.2 0.39 76.5 0.89 76 0.66 74.7 0.06 74.9 0.1 76.5 0.29 
No. HCUP 
comorbidities 
1.11 1.09 0.43 1.06 0.96 1.04 0.57 0.93 0.06 1.02 0.63 1 0.39 
RxRisk score 4.38 4.5 0.95 4.57 0.30 4.63 0.44 4.7 0.2 4.2 0.39 4.33 0.70 
Sex (male) 89 74 0.17 82 0.52 75 0.20 85 0.72 96 0.53 74 0.17 
Statin 
medications 
85 94 0.38 89 0.66 81 0.72 85 0.2 82 0.76 85 1 
Hospice care 2 2 1 1 1 2 1 3 1 5 0.25 2 1 
No. ED visits 0.11 0.18 0.80 1.12 0.7 0.17 0.04* 0.17 0.04* 0.17 0.2 0.12 0.39 
No. 
hospitalizations 
0.19 0.16 0.11 0.23 0.33 0.15 2.0 0.13 0.06 0.21 0.15 0.18 0.59 
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Table  B.l. (Continued) 
AChEI Gastrointestinal Psychological Respiratory Hepatic Hematologic Death 
Baseline Tx UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value 
No. with 84 84 1 
psychologic 
episode 





6 11 0.27 
Steroids 34 43 0.23 45 0.18 39 0.53 47 0.11 
NSAIDs 124 137 0.29 113 0.35 
Gastroprotective 
medications 
117 117 1 
Anxiolytics 103 103 1 98 0.67 111 0.49 88 0.19 109 0.60 
Anticonvulsants 85 81 0.71 90 0.66 98 0.25 97 0.29 77 0.43 
Parkinson's 37 26 0.19 40 0.81 
medications 
Antipsychotics 135 135 1 128 0.55 111 0.05 140 0.67 149 0.27 
Antidepressants 209 222 0.27 196 0.26 2.11 0.86 200 0.46 203 0.63 
Narcotics 157 165 0.53 157 1 159 0.87 161 0.76 165 0.53 
Sedatives 54 55 0.91 65 0.26 57 0.75 45 0.32 47 0.43 
le B.1  (Continued) 
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Table  B.l. (Continued) 
AChEI Gastrointestinal Psychological Respiratory Hepatic Hematologic Death 
Baseline Tx UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value 





deficiency  anemia 




















69 0.70 71 
0.61 11 
0.49 
70 0.92 77 0.05 
0.65 
62 0.38 
69 0.49 67 0.60 66 0.67 
6 0.61 
0.58 13 0.52 
44 0.65 40 0.87 28 0.22 
0.69 1 0.38 
67 0.30 47 0.35 
58 0.50 
68 0.76 66 0.63 
139 0.36 
56 0.53 58 0.67 
0.80 0.61 
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Table  B.l. (Continued) 
AChEI Gastrointestinal Psychological Respiratory Hepatic Hematologic Death 
Baseline Tx UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value 

























79 0.63 75 0.30 
11 0.34 
48 0.91 33 0.1 56 0.33 43 0.63 
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Table  B.l. (Continued) 
AChEI Gastrointestinal Psychological Respiratory Hepatic Hematologic Death 
Baseline Tx UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value UnTx P Value 
Diagnosed 12 11 1 6 0.18 13 1 13 1 
coagulation 
deficiency 
Diagnosed 18 19 1 16 0.86 19 1 
valvular disease 
Diagnosed weight 38 33 0.50 40 0.80 39 0.90 40 0.80 35 0.80 
loss 
AChEI = acetylcholinesterase inhibitors 
Tx = treated 
UnTx = untreated 
HCUP= Healthcare Cost and Utilization Project 
No. = number 
ED = emergency department 
NSAIDs = nonsteroidal anti-inflammatory  drug 
P Value = < 0.05 
l  B.l (Continued) 
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